|
|
|
Volumn , Issue , 2006, Pages
|
|
Genentech caps cost of cancer drug for some patients.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
ANTINEOPLASTIC AGENT;
BEVACIZUMAB;
MONOCLONAL ANTIBODY;
ARTICLE;
BREAST TUMOR;
COLORECTAL TUMOR;
DRUG COST;
DRUG INDUSTRY;
ECONOMICS;
GENENTECH INC.;
HEALTH CARE AND PUBLIC HEALTH;
HUMAN;
LUNG TUMOR;
POPULAR APPROACH/SOURCE;
REIMBURSEMENT;
GENENTECH INC.;
HEALTH CARE AND PUBLIC HEALTH;
POPULAR APPROACH/SOURCE;
ANGIOGENESIS INHIBITORS;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
BREAST NEOPLASMS;
COLORECTAL NEOPLASMS;
DRUG COSTS;
DRUG INDUSTRY;
HUMANS;
INSURANCE, HEALTH, REIMBURSEMENT;
LUNG NEOPLASMS;
|
|
EID: 33750608248
PISSN: 03624331
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (5)
|
|
References (0)
|
